GlassScriptPhysician profile
Bruce E Lewis
NPI 1538238050
$82,763.46
in general payments reported to CMS, 2019-2025
31 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $12K · 2021: $8,395 · 2022: $16K · 2023: $1,323 · 2024: $1,851 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $72,561.05 | 2019-2022 | |
| Abbott Laboratories | $2,576.70 | 2019-2025 | Mitraclip, Triclip, Amplatzer Amulet |
| Medtronic, INC. | $1,304.66 | 2021-2025 | Symplicity G3, In.Pact Admiral, Cg Future |
| Biotronik INC. | $1,179.08 | 2019-2023 | Orsiro Mission |
| Esperion Therapeutics, INC. | $634.46 | 2020-2024 | Nexletol |
| Edwards Lifesciences Corporation | $604.62 | 2023-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $510.17 | 2022-2025 | |
| Medtronic Vascular, INC. | $487.98 | 2019-2020 | |
| Lilly USA, LLC | $450.00 | 2019 | |
| Cardiovascular Systems INC. | $365.72 | 2019-2022 | |
| Inari Medical, INC. | $345.67 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Endologix LLC | $294.62 | 2024-2025 | Afx2 Bifurcated Endograft System, Torus Stent Graft System, Endocross Device |
| Ancora Heart, INC. | $166.43 | 2024 | Accucinch |
| Astrazeneca Pharmaceuticals LP | $156.54 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $133.64 | 2021-2023 | Camzyos |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.16 | 2019-2022 | |
| Boston Scientific Corporation | $122.68 | 2021-2024 | Watchman Access System, Ekosonic |
| Tempus Ai, INC | $121.57 | 2025 | Egg-Af |
| Abiomed | $114.92 | 2019-2024 | Impella |
| Penumbra, INC. | $100.00 | 2023 | Red 72 |
| Shockwave Medical, INC | $78.06 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $63.38 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $56.71 | 2023 | Arcalyst |
| Stryker Corporation | $54.19 | 2025 | Flowtriever |
| Biosense Webster, INC. | $35.82 | 2020-2024 | Na |
| Actelion Pharmaceuticals US, INC. | $27.15 | 2021 | |
| Teleflex LLC | $23.56 | 2024 | Turnpike |
| Terumo Medical Corporation | $20.20 | 2024 | Metacross Otw, Glidewire, Angio-Seal |
| Surmodics, INC. | $20.02 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.62 | 2023 | Inpefa |
| W. L. Gore & Associates, INC. | $13.08 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.